News & Updates

Show Multimedia Only
Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

10 Nov 2026 byAudrey Abella

In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.

10 Nov 2026
Tranquillo data support ritlecitinib for NSV

Tranquillo data support ritlecitinib for NSV

27 Oct 2026 byAudrey Abella

In two pivotal phase III Tranquillo studies, individuals with nonsegmental vitiligo (NSV) achieved significant and clinically meaningful improvements in facial and total body repigmentation after 52 weeks of treatment with oral ritlecitinib.

27 Oct 2026